- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 54,34 | -0,04 % | Dividendenbekanntmachungen (04.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN EXPRESS COMPANY US0258161092 0,82 USD 0,742 EUR BARCLAYS PLC GB0031348658 0,055 GBP EUR BRISTOL-MYERS SQUIBB COMPANY US1101221083 0... ► Artikel lesen | |
| GENMAB | 166,95 | -0,39 % | Genmab A/S: TIVDAK (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer | TIVDAK is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy In the global... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,890 | -2,23 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| MOLECULIN BIOTECH | 2,450 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial | - Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical... ► Artikel lesen | |
| VERICEL | 38,800 | +2,11 % | Vericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results | Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth of 58% to $53.4 Million Record Fourth... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,270 | +2,66 % | Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress | - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant "hot" tumor patient population - - Solnerstotug continues to demonstrate... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,602 | -6,23 % | MustGrow Biologics Corp.: MustGrow Adds New Biostimulants and Inoculants to Canadian Product Portfolio | Saskatoon, Saskatchewan--(Newsfile Corp. - April 1, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,950 | -100,00 % | BioXcel Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| REGENXBIO | 5,800 | +0,87 % | Regenxbio Aktie: Für und Wider der Marktentwicklungen | Regenxbio Inc. verzeichnete am vergangenen Handelstag einen leichten Rückgang. Die Aktie schloss am Freitag bei 7,25 Euro und verlor damit 1,36 Prozent. Im 30-Tages-Vergleich konnte das Biotechnologieunternehmen... ► Artikel lesen | |
| AKEBIA | 1,640 | +1,67 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa | CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 4,940 | -7,66 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update | ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 6,300 | -2,33 % | Zevra Therapeutics Files Preliminary Proxy | ||
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 07.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 07.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 07.02.2025ISIN NameCA09226M1005 BLACK... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 2,570 | -1,15 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results | Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and... ► Artikel lesen | |
| ADVERUM BIOTECHNOLOGIES | 3,500 | -6,91 % | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted an inducement... ► Artikel lesen |
Das Unternehmen BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,048 Euro und damit -3,68 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.
